Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 21, 2017; 23(43): 7727-7734
Published online Nov 21, 2017. doi: 10.3748/wjg.v23.i43.7727
Published online Nov 21, 2017. doi: 10.3748/wjg.v23.i43.7727
Figure 1 Changes in pediatric Crohn’s disease activity index before and after 9-12 mo of thalidomide treatment in 10 patients.
There was a decrease of the pediatric CD activity index (PCDAI) scores in 9 patients (P < 0.05), 6 of them achieved clinical remission (PCDAI < 10). PCDAI: Pediatric Crohn’s disease activity index.
Figure 2 Changes of laboratory indices before and after 9-12 mo treatment in 10 Crohn’s disease patients with tuberculosis.
A: Erythrocyte sedimentation rate (ESR); B: C-reactive protein (CRP); C: Hemoglobin (Hb); D: Platelet (PLT). It showed significant reductions in ESR, CRP and platelet levels (P < 0.05); and an increasing trend in Hb levels.
Figure 3 Changes in weight for age Z score before and after 9-12 mo treatment in 10 cases treated with thalidomide.
- Citation: Wang L, Hong Y, Wu J, Leung YK, Huang Y. Efficacy of thalidomide therapy in pediatric Crohn’s disease with evidence of tuberculosis. World J Gastroenterol 2017; 23(43): 7727-7734
- URL: https://www.wjgnet.com/1007-9327/full/v23/i43/7727.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i43.7727